SER Relative Valuation
SER's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SER is overvalued; if below, it's undervalued.
Historical Valuation
Serina Therapeutics Inc (SER) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.31. The fair price of Serina Therapeutics Inc (SER) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：3.49
Fair
-1.87
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Serina Therapeutics Inc. (SER) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-1.26
EV/EBIT
Serina Therapeutics Inc. (SER) has a current EV/EBIT of -1.26. The 5-year average EV/EBIT is -0.85. The thresholds are as follows: Strongly Undervalued below -2.76, Undervalued between -2.76 and -1.81, Fairly Valued between 0.10 and -1.81, Overvalued between 0.10 and 1.05, and Strongly Overvalued above 1.05. The current Forward EV/EBIT of -1.26 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Serina Therapeutics Inc. (SER) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
-1.49
P/OCF
Serina Therapeutics Inc. (SER) has a current P/OCF of -1.49. The 5-year average P/OCF is -1.00. The thresholds are as follows: Strongly Undervalued below -3.23, Undervalued between -3.23 and -2.11, Fairly Valued between 0.12 and -2.11, Overvalued between 0.12 and 1.24, and Strongly Overvalued above 1.24. The current Forward P/OCF of -1.49 falls within the Historic Trend Line -Fairly Valued range.
-1.34
P/FCF
Serina Therapeutics Inc. (SER) has a current P/FCF of -1.34. The 5-year average P/FCF is -0.90. The thresholds are as follows: Strongly Undervalued below -3.03, Undervalued between -3.03 and -1.97, Fairly Valued between 0.16 and -1.97, Overvalued between 0.16 and 1.23, and Strongly Overvalued above 1.23. The current Forward P/FCF of -1.34 falls within the Historic Trend Line -Fairly Valued range.
Serina Therapeutics Inc (SER) has a current Price-to-Book (P/B) ratio of -11.54. Compared to its 3-year average P/B ratio of 1.81 , the current P/B ratio is approximately -739.13% higher. Relative to its 5-year average P/B ratio of 1.81, the current P/B ratio is about -739.13% higher. Serina Therapeutics Inc (SER) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -23.98%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -23.98% , the current FCF yield is about -100.00% lower.
-11.50
P/B
Median3y
1.81
Median5y
1.81
-44.66
FCF Yield
Median3y
-23.98
Median5y
-23.98
Competitors Valuation Multiple
The average P/S ratio for SER's competitors is 0.00, providing a benchmark for relative valuation. Serina Therapeutics Inc Corp (SER) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of SER decreased by 30.74% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -0.46 to -1.81.
The secondary factor is the Revenue Growth, contributed -100.00%to the performance.
Overall, the performance of SER in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Serina Therapeutics Inc (SER) currently overvalued or undervalued?
What is Serina Therapeutics Inc (SER) fair value?
How does SER's valuation metrics compare to the industry average?
What is the current P/B ratio for Serina Therapeutics Inc (SER) as of Dec 05 2025?
What is the current FCF Yield for Serina Therapeutics Inc (SER) as of Dec 05 2025?
What is the current Forward P/E ratio for Serina Therapeutics Inc (SER) as of Dec 05 2025?